| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 836.0 | 904.0 |
| Gross profit | 443.0 | 441.0 |
| Profit before tax | 26.0 | -230.0 |
| Net income | -2.0 | -427.0 |
| EPS (diluted, $ a share) | $-0.01 | $-2.14 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -7.5% |
|---|---|
| Gross margin | 53.0% |
| Operating margin | 4.4% |
10-Q filed with the SEC, NASDAQ: XRAY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Dentsply Sirona Inc.: key numbers
- Share price
- $8.94Close, Nov 16
- Market cap
- $1.77B
- Shares outstanding
- 198.15MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Dental Equipment & SuppliesSIC 3843
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Dentsply Sirona Inc.
All →Dentsply Sirona Financial Results
Dentsply Sirona reported Q3 2026 net sales of $836 million, a 7.6% decrease year-over-year, and a GAAP diluted loss per share of $0.01. Despite challenging industry conditions, the company highlighted record quarterly sales for its Wellspect Healthcare segment and updated its full-year 2026 outlook.
- Term
- Q3 2026
“We continued to make progress on our Return-to-Growth Action Plan in the third quarter despite challenging industry-wide conditions. We are seeing encouraging signs of progress, including record quarterly sales for Wellspect Healthcare, progress in priority areas of implants and endodontics, and broader customer access through our expanded U.S. dealer network. Building on the investments we began in the first half, our focus is now on execution, putting our sales force, clinical education and innovation capabilities to work to drive consistent performance and sustainable growth.”
Dan Scavilla, President and Chief Executive Officer
Dentsply Sirona Debt Financing Update with JPMorgan Chase Bank, N.A.
DENTSPLY SIRONA Inc. entered into amendments for its revolving credit facility and three separate note purchase agreements to increase its maximum permitted leverage ratios for the second half of 2026. The amendments also include EBITDA addbacks for certain cash charges and impose temporary restrictions on new liens, subsidiary debt, and restricted payments. These changes are intended to ensure the company maintains compliance with its debt covenants through the end of the fiscal year.
- Counterparty
- JPMorgan Chase Bank, N.A.